Small Stocks BIG Returns

Two Outta’ Three Isn’t Bad: ZLCS, VPRO, and WZE in Focus
/

January 18, 2025

/

04:33 AM PST

Small caps Viropro, Inc. (VPRO), Wizzard Software Corporation (WZE), and Zalicus, Inc. (ZLCS) are Tuesday’s hot topics. Here’s the deal.

Folks, get ready to rumble… for better or worse. The shortened trading week is still poised to be an explosive one, with small stocks Zalicus, Inc. (NASDAQ: ZLCS), Wizzard Software Corporation (AMEX: WZE), and Viropro, Inc. (PINK: VPROout in front and ready to lead the charge higher or lower, as the case may be. Take a look.

First and foremost, yes, I was the same guy who in late March was talking bullishly about Wizzard Software Corporation. Though it didn’t get above my mental line in the sand at $0.30 (at least not on a permanent basis) to officially become a trade, I have to tale credit at least for my perspective on WZE… good or bad. On the flipside, when I put an equally-bearish perspective on this small cap back in early May, I got verbally hammered. Those same folks shut up pretty quickly though, when my floor at $0.17/$0.18 did indeed break and sent this stock to a low of $0.13. In the meantime, the chart’s fought its way back above the $0.18 level, though only after a real battle.

So what? The moral of the story is just that WZE is a great ‘trading’ stock in that it makes predictable moves above and below key horizontal levels. The fact that it punched above $0.18 (which is also where the 50-day average line was) bodes well for Wizzard Software Corporation…. especially after a sharp reversal move in early June. Definitely a case of “don’t think too much.”

If you’re like even the most enthusiastic of small cap aficionados, you’ve probably never heard of Viropro. That’s ok. Though VPRO has been trading for years, it’s only been effectively trading (on any meaningful volume) since the beginning of this year. That’s when the company, aka Alpha Biologics after a name change last month, inked a deal with Spectrum Pharmaceuticals to do for the what it ‘does’…which is offer technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases. Now, if you know what that means simply from reading it one time, get a life. For the rest of us, it means that Viropro Inc. helps other biopharma companies make drugs to use in their own pre-clinical, Phase1, and clinical trials.

Anyway, though it’s been erratic to be sure, VPRO has also been taking two steps forward and one step back on a pretty reliable basis since January. The result is the development of a rising support line (purple), and a near-term horizontal ceiling at $0.06. If that level, and then the $0.086 mark can be knocked over, Viropro could take off. I’d rather be in this small cap stock before then though.

Last but not least, I came within a hair of posting a bearish outlook on small stock Zalicus. Then today’s 10% pop materialized, and I had to rethink things; kinda hard to go against the grain when the grain is that strong. That said, it’s not like I’m lettin’ ZLCS off the hook just yet.

The fact of the matter is, despite today’s advance, ZLCS is looking a little head-and-shoulder-ish. Oh sure, there are now five shoulders for the one head, and two potential necklines (orange and red), but the spirit of the signal is more important than its perfection…. maybe. In this case, the spirit of Zalicus says the highs and lows are getting lower.

As overbought as ZLCS is, and assuming the horizontal ceiling (blue) at $2.55 can keep a lid on things today, a break under that lower support line (the so-called ‘neckline’) around $2.06 would pretty much cook the goose here. The 200-day average will be there by the time it can be tested. Anything else and the bulls still have a fighting chance.

Tags

Join our community to participate in comments, rate stocks, receive daily updates, and more.
?